Roughly 150 people at Pfizer's Portage factory are now out of a job.

Below are News Channel 3's top stories from the past week.

Pfizer's NYSE Composite context covers pharmaceutical operations, Tukysa approval, oncology research, vaccine development, patent exclusivity and dividend commitments across global healthcare markets.

Pfizer (NYSE:PFE) raised its revenue guidance in the second quarter of 2026, held its earnings guidance and announced another ...

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer ...

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

A few months ago I sat through a marketing plan presentation that could have been delivered, almost word for word, in 1975.

Enodia Therapeutics and Pfizer sign a research and license deal worth over $500M to develop Sec61 translocon inhibitors. Read ...

The SIT investigating the alleged fake pharmaceutical racket helmed by a former medical representative based in Karnataka has said that the probe traced overseas links in Turkiye who supplied original ...

Amylin analog obesity therapeutics market to grow from USD 140.0 Mn in 2026 to USD 1,324.9 Mn by 2036 at a 25.2% CAGR. Get ...

Florida has sued Pfizer and CEO Albert Bourla, alleging the company misled consumers about its COVID-19 vaccine. Pfizer denies the accusations, which have not been proven in court.

Beijing proposes controls on five biomedical technologies but exempts licensing, partnerships and contract research, keeping ...